The power of r – pharmaceutical sales decomposition in Cyprus public healthcare sector and determinants of drug expenditure evolution: any lessons learned?-Reference-Cited by-同舟云学术

The power of r – pharmaceutical sales decomposition in Cyprus public healthcare sector and determinants of drug expenditure evolution: any lessons learned?

Published:2014-03-03 Issue:2 Volume:14 Page:289-300
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Petrou Panagiotis

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737167.2014.889565

Reference55 articles.

1. Evaluating health interventions: exploiting the potential

2. Explaining Drug Spending Trends: Does Perception Match Reality?

3. Strategic Pricing of New Pharmaceuticals

4. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

5. How innovative are pharmaceutical innovations? The case of medicines financed through add-on payments outside of the French DRG-based hospital payment system

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Main drivers of diabetes pharmaceuticals expenditures: evidence from OECD countries and Iran;Journal of Diabetes & Metabolic Disorders;2022-12-22

2. Price Determinants of the Tendering Process for Pharmaceuticals in the Cyprus Market;Value in Health Regional Issues;2015-09

3. Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform;Bulletin of the World Health Organization;2015-06-18

4. Cost-effectiveness analysis of axitinib through a probabilistic decision model;Expert Opinion on Pharmacotherapy;2015-05-09

5. Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment;Health Policy;2015-05